Incredible Growth of Human Growth Hormone Market Size, Share, Trends, Analysis and Forecast 2027| Pfizer Inc., Genetech Inc., Merck & Co., Eli Lilly And Company, Novo Nordisk, Sandoz International GmbH, Ferring Holding SA, and Ipsen.

The "Global Human Growth Hormone Market: 2020" Industry Report is a professional and in-depth study on the current state of the Human Growth Hormone Market by CMI. The Human Growth Hormone market is supposed to demonstrate a considerable growth during the forecast period of 2020 - 2027. The company profiles of all the key players and brands that are dominating the market have been given in this report. Their moves like product launches, joint ventures, mergers and acquisitions and the respective effect on the sales, import, export, revenue and CAGR values have been studied completely in the report. The scope of this Human Growth Hormone market report can be expanded from market scenarios to comparative pricing between major players. The emerging trends along with major drivers, challenges and opportunities in the market are also identified and analysed in this report.

Human Growth Hormone help organizations to develop cogent, coherent plans of action to improve their performance.

To Gain More Insights into the Market with Detailed Table of Content and Figures, Click Here -https://www.coherentmarketinsights.com/ongoing-insight/human-growth-hormone-market-1859

Human growth hormone is a peptide hormone that is naturally produced in the pituitary glands. It stimulates growth, cell reproduction, and cell regeneration. The somatotropic cells within the lateral wings of anterior pituitary gland store and secrete growth hormone. These hormones are responsible for general growth of the body and mineralization of the bones. Growth hormones also help to retain calcium in the body and increases muscle mass through sarcomere hypertrophy. The hormones promote lipolysis, increase protein synthesis, and stimulate growth of all internal organs excluding the brain. Growth hormones are responsible for homeostasis, decrease in uptake of glucose by liver, stimulation in the immune system, and increase of DE iodination of T4 to T3.

However, uncontrolled or excess secretion of growth hormones can lead to pituitary tumor, which consists of somatotroph cells of the anterior pituitary. These somatotroph cells are benign in nature and gradually grow and produce excess of growth hormones. This may often lead to headaches, pressure on optic nerves causing impaired vision, deficiency of other hormones secreted by pituitary gland, and thickening of the bones of jaw, toes, and fingers, which eventually results in heaviness of jaws and increase in size of digits called as acromegaly. Acromegaly can further lead to pressure on nerves, muscle weakness, and reduced sexual function. Growth hormone deficiency is associated with failure in growth, increase in osteoclast activities, weakening of bones, trauma, increase in fat mass, and decrease in muscle mass.

Request a PDF Sample Copy of the Research Report: https://www.coherentmarketinsights.com/insight/request-sample/1859

This report sample includes
--Brief Introduction to the research report.
--Table of Contents (Scope covered as a part of the study)
--Top players in the market
--Research framework (presentation)
--Research methodology adopted by Coherent Market Insights

Human Growth Hormone Market Drivers:-

Key players in the market are focused on adopting merger and acquisition strategies, which is expected to boost growth of the market. For instance, in 2014, Pfizer Inc., a U.S.-based pharmaceutical company, merged with OPKO Health Inc., a U.S.-based company, to develop a long acting growth hormone (hGH-CTP) and to bring innovative treatments for growth hormone deficient patients. hGH-CTP is more convenient, as the patients need to take just one injection in a week rather than daily doses. hGH-CTP has an orphan drug designation in the U.S. and Europe for adults and children with growth hormone deficiency.

Robust pipeline of advanced products for the treatment of growth hormone deficiency is also expected to propel growth of the market. For instance, Somapacitan sponsored by Novo Nordisk A/S, a Denmark-based company, completed phase 3 clinical trials in 2017. This drug is used for the treatment of growth hormone deficiency in adults. MOD-4023 sponsored by Opko Biologics, an Israel-based company, completed phase 2 clinical trials in 2015. High prevalence of growth hormone deficiency is another factor boosting growth of human growth hormone market. According to a survey conducted by the National Organization for Rare Diseases (NORA) in 2015, over 10,000 children and 50,000 adults have growth hormone deficiency in the U.S.

However, stringent rules and regulations for the use of human growth hormone is expected to hamper the market growth. For instance, in 2006, the U.S. Food and Drug Administration (FDA) and the International Olympic Committee banned the use of human growth hormone for sports professionals.

The key players profiled in this report include:
-Pfizer Inc.
-Genetech Inc.
-Merck & Co.
-Eli Lilly And Company
-Novo Nordisk
-Sandoz International GmbH
-Ferring Holding SA
-Ipsen.

Regions included:

o North America (United States, Canada, and Mexico)
o Europe (Germany, France, UK, Russia, and Italy)
o Asia-Pacific (China, Japan, Korea, India, and Southeast Asia)
o South America (Brazil, Argentina, Colombia)
o Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria, and South Africa)

Human Growth Hormone Market Taxonomy:-
By Application
o Growth Hormone Deficiency
o Idiopathic short stature
o Prader-Willi Syndrome
o Turner Syndrome
o Others

By Route of Administration
o Oral
o Intravenous
o Subcutaneous
o Intramuscular

By Distribution Channel
o Hospitals
o Retail Pharmacies
o Online Pharmacies

Human Growth Hormone Market Regional Analysis:-

North America is expected to hold dominant position in the global human growth hormone market. This is attributed to approval of new biosimilars. For instance, in 2015, Health Canada approved the first generic biological called as PROmnitrope. PROmnitrope is a recombinant human growth hormone used to treat deficiency of growth hormone in adults as well as children. This can encourage new generic version of drugs, thereby fueling the human growth hormone market growth.

Buy This Research Study Report @ https://www.coherentmarketinsights.com/insight/buy-now/1859

Key players in the Europe market are focused on adopting merger and acquisition strategies, which is expected to contribute to growth of the market. For instance, in 2017, Ferring Pharmaceuticals S.A., a pharmaceutical company, acquired a product i.e. Zoma Jet of Antares Pharma Inc, a pharmaceutical company. Zoma Jet is a needle free auto injectable device. Ferring Pharmaceuticals S.A acquired Zoma Jet in order to increase use of Zomacton (Injectable somatropin hGH). Zoma Jet is used to deliver Zomacton for the treatment of growth hormone deficiency in children and Turner's syndrome in girls. By acquiring the injectable device Zoma Jet, would eventually lead to increase in use of the drug, Zomacton, which will further encourage Ferring Pharmaceuticals to develop better treatment options for growth hormone deficiency, thereby resulting in growth of the human growth hormone market. Asia Pacific is expected to grow over the forecast period due to robust pipeline. For instance, Cinna Tropin sponsored by Cinnagen, an Iran-based company, completed phase 3 clinical trials in 2017. This drug is used to treat idiopathic short stature in children and adults.

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us:
sales@coherentmarketinsights.com

U.S. Office:
Name: Mr. Shah
Coherent Market Insights 1001 4th Ave,
# 3200 Seattle, WA 98154, U.S.
US : +1-206-701-6702
UK : +44-020-8133-4027
JAPAN : +050-5539-1737

This release was published on openPR.